The Effects of Glycemic Optimization Before Gastric Bypass Surgery (GLUCOSURG2)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2013 by Imperial College London.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Imperial College London
Information provided by (Responsible Party):
Carel Le Roux, Imperial College London
ClinicalTrials.gov Identifier:
NCT01353118
First received: May 11, 2011
Last updated: January 1, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Metabolic surgery such as gastric bypass, gastric banding or sleeve gastrectomy operations can cause rapid and uncontrolled reductions in blood glucose. There is limited information on whether:
- metabolic surgery is superior to modern medical care for glycaemic control and type 2 diabetes remission.
- metabolic surgery is safe for microvascular complications of Type 2 diabetes
- good glycaemic control pre surgery has any effects on the long term glycaemia and complications of type 2 diabetes.
This study aims to assess:
- whether metabolic surgery is better for diabetes control compared to medical treatment.
- whether metabolic surgery is safe for eye, nerve and kidney complications.
- whether good sugar control before metabolic surgery improves the long term effects of sugar control and microvascular complications.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes |
Biological: Glycaemic optimisation before surgery |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Investigation of the Effects of Glycaemic Optimisation Before Gastric Bypass Surgery on the Glycaemic Remission and Microvascular Complication Rates of Type 2 Diabetes Mellitus |
Resource links provided by NLM:
Further study details as provided by Imperial College London:
Primary Outcome Measures:
- Composite of fasting glucose, glycosylated haemoglobin c and rates of Type 2 Diabetes mellitus remission. [ Time Frame: 1 year ] [ Designated as safety issue: No ]Fasting glucose and HbA1c 1 year after intervention / metabolic surgery. Remission of diabetes will be based on the American Diabetes Association definition.
Secondary Outcome Measures:
- A composite of microvascular complications [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]A composite of microvascular complications. Microvascular events will be defined as new or worsening nephropathy, retinopathy or neuropathy.
| Estimated Enrollment: | 150 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Gastric bypass without pre op glycaemic optimisation
Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
|
|
|
Active Comparator: Gastric bypass with pre op glycaemic optimisation
Group B:Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
|
Biological: Glycaemic optimisation before surgery
Optimise glucose control within 3 months before operation
Other Names:
|
|
No Intervention: Best medical care for Type 2 Diabetes Mellitus
Group C: Obese patients with T2DM (who choose not to have surgery) will be treated with best medical care based on the ADA/EASD guidelines including anti-diabetes/obesity pharmacotherapy, access to a trained dietician and exercise programme.
|
Detailed Description:
This is a prospective study involving 150 patients with type 2 diabetes mellitus (T2DM) and obesity. One hundred patients will undergo gastric bypass surgery whilst 50 will be treated with best medical care. The surgical patient group will be randomised to either immediate surgery or 3 months of medical glycaemic optimisation followed by surgery (n=50 group).
Intervention Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
Group B: Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved with particular attention to the avoidance of hypoglycaemia.
Group C: Obese patients with T2DM (who choose not to have surgery) will be treated with best medical care based on the ADA/EASD guidelines including anti-diabetes/obesity pharmacotherapy, access to a trained dietician and exercise programme.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult patients with T2DM and BMI above 35kg/m2
- HbA1c ≥ 8.5% and/or the presence of at least one microvascular complication.
Exclusion Criteria:
- End stage retinopathy, nephropathy or neuropathy.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353118
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353118
Locations
| United Kingdom | |
| Charing Cross Hospital | |
| London, United Kingdom, W6 8RF | |
| Imperial Weight Centre, Charing Cross Hospital, | |
| London, United Kingdom, W6 8FR | |
Sponsors and Collaborators
Imperial College London
Investigators
| Principal Investigator: | Carel Le Roux, MBChB, PhD | Imperial College London |
More Information
No publications provided
| Responsible Party: | Carel Le Roux, Consultant metabolic medicine, Imperial College London |
| ClinicalTrials.gov Identifier: | NCT01353118 History of Changes |
| Other Study ID Numbers: | GLUCOSURG 2 |
| Study First Received: | May 11, 2011 |
| Last Updated: | January 1, 2013 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by Imperial College London:
|
diabetes bariatric surgery Roux-en-y gastric bypass |
retinopathy neuropathy nephropathy |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on February 27, 2015